|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
|
|
2
|
Gu J, Ding JY, Lu CL, et al:
Overexpression of CD88 predicts poor prognosis in non-small-cell
lung cancer. Lung Cancer. 81:259–265. 2013.
|
|
3
|
Edelman MJ: Novel taxane formulations and
microtubule-binding agents in non-small-cell lung cancer. Clin Lung
Cancer. 10:S30–S34. 2009.
|
|
4
|
Morales-Cano D, Calviño E, Rubio V, et al:
Apoptosis induced by paclitaxel via Bcl-2, Bax and caspases 3 and 9
activation in NB4 human leukaemia cells is not modulated by ERK
inhibition. Exp Toxicol Pathol. 65:1101–1108. 2013.
|
|
5
|
Kavallaris M: Microtubules and resistance
to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010.
|
|
6
|
Wan YF, Guo XQ, Wang ZH, Ying K and Yao
MH: Effects of paclitaxel on proliferation and apoptosis in human
acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 25:378–384.
2004.
|
|
7
|
Xu R, Sato N, Yanai K, et al: Enhancement
of paclitaxel-induced apoptosis by inhibition of mitogen-activated
protein kinase pathway in colon cancer cells. Anticancer Res.
29:261–270. 2009.
|
|
8
|
Kastl L, Brown I and Schofield AC: Altered
DNA methylation is associated with docetaxel resistance in human
breast cancer cells. Int J Oncol. 36:1235–1241. 2010.
|
|
9
|
Le XF and Bast RC Jr: Src family kinases
and paclitaxel sensitivity. Cancer Biol Ther. 12:260–269. 2011.
|
|
10
|
Modok S, Mellor HR and Callaghan R:
Modulation of multidrug resistance efflux pump activity to overcome
chemoresistance in cancer. Curr Opin Pharmacol. 6:350–354.
2006.
|
|
11
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012.
|
|
12
|
Volinia S, Calin GA, Liu CG, et al: A
microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
|
|
13
|
Jiang P, Liu R, Zheng Y, et al: MiR-34a
inhibits lipopolysaccharide-induced inflammatory response through
targeting Notch1 in murine macrophages. Exp Cell Res.
318:1175–1184. 2012.
|
|
14
|
Zheng Y, Xiong S, Jiang P, et al:
Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory
response by downregulating microRNA-155: a novel anti-inflammation
mechanism. Free Radic Biol Med. 52:1307–1317. 2012.
|
|
15
|
Haenisch S and Cascorbi I: miRNAs as
mediators of drug resistance. Epigenomics. 4:369–381. 2012.
|
|
16
|
Schoof CR, Botelho EL, Izzotti A and
Vasques Ldos R: MicroRNAs in cancer treatment and prognosis. Am J
Cancer Res. 2:414–433. 2012.
|
|
17
|
Miller TE, Ghoshal K, Ramaswamy B, et al:
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by
targeting p27Kip1. J Biol Chem. 283:29897–29903. 2008.
|
|
18
|
Takwi AA, Wang YM, Wu J, et al: miR-137
regulates the constitutive androstane receptor and modulates
doxorubicin sensitivity in parental and doxorubicin-resistant
neuroblastoma cells. Oncogene. 2013.
|
|
19
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013.
|
|
20
|
Pan YZ, Morris ME and Yu AM: MicroRNA-328
negatively regulates the expression of breast cancer resistance
protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol.
75:1374–1379. 2009.
|
|
21
|
Liang Z, Wu H, Xia J, et al: Involvement
of miR-326 in chemotherapy resistance of breast cancer through
modulating expression of multidrug resistance-associated protein 1.
Biochem Pharmacol. 79:817–824. 2010.
|
|
22
|
Kastl L, Brown I and Schofield AC:
miRNA-34a is associated with docetaxel resistance in human breast
cancer cells. Breast Cancer Res Treat. 131:445–454. 2012.
|
|
23
|
Xiong S, Zheng Y, Jiang P, Liu R, Liu X
and Chu Y: MicroRNA-7 inhibits the growth of human non-small cell
lung cancer A549 cells through targeting BCL-2. Int J Biol Sci.
7:805–814. 2011.
|
|
24
|
Xiong S, Zheng Y, Jiang P, Liu R, Liu X,
Qian J, Gu J, Chang L, Ge D and Chu Y: PA28gamma emerges as a novel
functional target of tumor suppressor microRNA-7 in non-small-cell
lung cancer. Br J Cancer. 110:353–362. 2014.
|
|
25
|
Nordentoft I, Birkenkamp-Demtroder K,
Agerbæk M, et al: miRNAs associated with chemo-sensitivity in cell
lines and in advanced bladder cancer. BMC Med Genomics.
5:402012.
|
|
26
|
Tian W, Chen J, He H and Deng Y: MicroRNAs
and drug resistance of breast cancer: basic evidence and clinical
applications. Clin Transl Oncol. 15:335–342. 2013.
|
|
27
|
Zhang Y, Hu H, Song L, Cai L, Wei R and
Jin W: Epirubicin-mediated expression of miR-302b is involved in
osteosarcoma apoptosis and cell cycle regulation. Toxicol Lett.
222:1–9. 2013.
|
|
28
|
Costa PM, Cardoso AL, Nóbrega C, et al:
MicroRNA-21 silencing enhances the cytotoxic effect of the
antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet.
22:904–918. 2013.
|
|
29
|
Duncavage E, Goodgame B, Sezhiyan A,
Govindan R and Pfeifer J: Use of microRNA expression levels to
predict outcomes in resected stage I non-small cell lung cancer. J
Thorac Oncol. 5:1755–1763. 2010.
|
|
30
|
Rai K, Takigawa N, Ito S, et al: Liposomal
delivery of MicroRNA-7-expressing plasmid overcomes epidermal
growth factor receptor tyrosine kinase inhibitor-resistance in lung
cancer cells. Mol Cancer Ther. 10:1720–1727. 2011.
|
|
31
|
Kefas B, Godlewski J, Comeau L, et al:
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008.
|
|
32
|
Webster RJ, Giles KM, Price KJ, et al:
Regulation of epidermal growth factor receptor signaling in human
cancer cells by microRNA-7. J Biol Chem. 284:5731–5741. 2009.
|
|
33
|
Chou YT, Lin HH, Lien YC, et al: EGFR
promotes lung tumorigenesis by activating miR-7 through a
Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor
ERF. Cancer Res. 70:8822–8831. 2010.
|
|
34
|
Merlo V, Longo M, Novello S and Scagliotti
GV: EGFR pathway in advanced non-small cell lung cancer. Front
Biosci (Schol Ed). 3:501–517. 2011.
|
|
35
|
Petitprez A and Larsen AK: Irinotecan
resistance is accompanied by upregulation of EGFR and Src signaling
in human cancer models. Curr Pharm Des. 19:958–964. 2013.
|
|
36
|
Rekhtman N, Paik PK, Arcila ME, et al:
Clarifying the spectrum of driver oncogene mutations in
biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS
and presence of PIK3CA/AKT1 mutations. Clin Cancer Res.
18:1167–1176. 2012.
|
|
37
|
Tanaka K, Babic I, Nathanson D, et al:
Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that
promotes chemotherapy resistance. Cancer Discov. 1:524–538.
2011.
|
|
38
|
Lee KM, Choi EJ and Kim IA: microRNA-7
increases radiosensitivity of human cancer cells with activated
EGFR-associated signaling. Radiother Oncol. 101:171–176. 2011.
|
